Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.

Abstract

Up to 30% of patients taking antipsychotics may develop tardive dyskinesia (TD). Recent evidence-based recommendations demonstrate an unmet need for effective TD management. This systematic review was designed to update the evidence for TD treatment, comparing two vesicular monoamine transporter 2 (VMAT2) inhibitors, tetrabenazine and valbenazine. Of 487 PubMed/Embase search results, 11 studies met the review criteria. Valbenazine efficacy was demonstrated in rigorously designed clinical trials that meet the guidelines for AAN Class I evidence. Due to differences in study designs and a lack of standardized and controlled trials with tetrabenazine, a formal meta-analysis comparing the agents was not possible. However, valbenazine appears to have fewer side effects and a more favorable once-daily dosing regimen for the treatment of TD.

DOI: 10.2217/cer-2017-0065

Cite this paper

@article{Caroff2017TreatmentOT, title={Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.}, author={Stanley N Caroff and Saurabh Aggarwal and Charles Yonan}, journal={Journal of comparative effectiveness research}, year={2017} }